James Shannon, M.D. Discloses Dealing with Horizon Therapeutics plc

James Shannon, M.D., a director of Horizon Therapeutics plc, has disclosed his dealing with the company’s securities. Under Rule 8.1(c) and (d)(i) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, Dr. Shannon revealed his interests and short positions in Horizon Therapeutics’ ordinary shares.

As of September 29, 2023, Dr. Shannon owns and/or controls 101,121 ordinary shares, representing 0.044% of the total shares. He did not disclose any cash-settled derivatives or stock-settled derivatives.

Furthermore, Dr. Shannon exercised 11,850 vested incentive stock options (ISO) for Horizon Therapeutics’ ordinary shares at a price of US$12.19 per share.

The disclosure was made in accordance with the regulatory requirements, and Dr. Shannon has provided all necessary information as per the rules.

For more details on the disclosure, please refer to the official press release.